Investing In Life Sciences De Novo
This article was originally published in Start Up
In the last two years, several major venture capital firms that had previously been major investors in life sciences companies abandoned health care for the rarified worlds of information technology and telecommunications. This created a void in health care investing that has seen two venture firms formed recently to focus exclusively on life sciences. First was Versant Ventures (formerly Palladium), which was started in September 1999 by the life sciences partners from Brentwood, IVP and Crosspoint Ventures. And more recently, in February 2000, four veterans of the life science investing wars--John Simpson, MD, Fred Dotzler, Richard Ferrari and David Mauney, MD--got together to form De Novo Ventures, which is also health care-focused. In addition to providing financing, De Novo is also looking to take advantage of the extensive operational experience of its partners by providing start-ups with hands-on management expertise.
You may also be interested in...
At In3 West, a medical device conference held in Las Vegas recently, Windhover Information convened a panel of venture investors to ask them what's in store for device companies seeking investments in the near future, and to address one nagging question: whether or not the heady funding levels of 2007 are sustainable, or even desirable. Certainly exits have become more challenging; consolidation has removed certain would-be acquirers and the IPO market has become more demanding; no company will get out there without at least $30 to $40 million in revenues, several on the panel felt. Others were feeling the pressure of having to carry portfolio companies for even longer periods of time; more complex technologies, lag times at the FDA, and the need to get companies not only to the commercial stage but to a revenue ramp were pushing up the number of years to an exit and total investment dollars. Many were optimistic that early stage deals, exits by acquisition and other unusual phenomena would continue to happen; but selectivity was the theme of the day.
Venture debt has become an increasingly popular financing option particularly among device companies. But, if not used properly, it can help sink rather than save a start-up.
Regulatory requirements for devices are becoming more demanding, making clinical trials more complex and costly. ThreeWire's marketing-based approach looks to speed patient recruitment, a benefit for start-ups since, in clinical studies, time is definitely money.